Volume 17, Number 6—June 2011
Dispatch
Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland
Table 1
Population characteristics in a study of prevalence and role of HEV infection among participants in the Swiss HIV Cohort Study, Switzerland, 2008*
Characteristic | No. (%) all participants, N = 735 | No. (%) HEV negative, n = 716 | No. (%) HEV positive, n = 19 | p value |
---|---|---|---|---|
Sex | 0.0587 | |||
M | 618 (84.1) | 605 (84.5) | 13 (68.4) | |
F |
117 (15.9) |
111 (15.5) |
6 (31.6) |
|
Ethnic group | <0.0001 | |||
White | 607 (82.6) | 594 (83.0) | 14 (73.7) | |
Black | 70 (9.5) | 69 (9.6) | 1 (5.3) | |
Hispanic | 26 (3.5) | 25 (3.5) | 1 (5.3) | |
Asian | 29 (3.9) | 26 (3.6) | 3 (15.8) | |
Other |
3 (0.4) |
2 (0.28) |
1 (0.14) |
|
Probable route of HIV infection | NS | |||
Heterosexual | 291 (39.6) | 283 (39.5) | 8 (42.1) | |
MSM | 411 (55.9) | 400 (55.9) | 11 (57.9) | |
IDU | 4 (0.6) | 4 (0.6) | 0 | |
Blood | 5 (0.7) | 5 (0.7) | 0 | |
Unknown/other |
24 (3.2) |
24 (3.4) |
0 |
|
Current or past IDU | NS | |||
Yes | 14 (2.3) | 14 (2.0) | 0 | |
No |
721 (99.7) |
702 (98.0) |
19 (100.0) |
|
Prison history | NS | |||
Yes | 45 (6.1) | 44 (6.1) | 1 (5.3) | |
No |
690 (93.9) |
672 (93.9) |
18 (94.7) |
|
Alcohol consumption | NS | |||
Yes | 261 (35.5) | 256 (35.8) | 5 (26.3) | |
No |
474 (64.5) |
460 (64.2) |
14 (73.7) |
|
BMI group, kg/m2 | NS | |||
<25 | 408 (55.5) | 398 (55.6) | 10 (52.6) | |
25.1–30 | 231 (31.4) | 225 (31.4) | 6 (31.6) | |
>30 |
96 (13.1) |
93 (12.9) |
3 (15.8) |
|
ALT peak value, IU/L | NS | |||
<180 | 606 (82.4) | 591 (82.5) | 15 (78.95) | |
>180 |
129 (17.6) |
125 (17.5) |
4 (21.05) |
|
Lowest CD4 count, cells/mm3 | 0.0685 | |||
<100 | 276 (37.6) | 273 (38.1) | 3 (15.8) | |
100–350 | 288 (39.2) | 276 (38.6) | 12 (63.2) | |
>350 |
171 (23.2) |
167 (23.3) |
4 (21.1) |
|
HAART history | NS | |||
Yes | 610 (83.0) | 595 (75.4) | 15 (78.9) | |
No |
125 (17.0) |
121(16.9) |
4 (21.6) |
|
Cancer occurrence | NS | |||
Yes | 25 (3.4) | 24 (3.4) | 1 (5.3) | |
No |
710 (96.6) |
692 (94.6) |
18 (94.7) |
|
Outcome | NS | |||
Dead | 29 (3.9) | 28 (3.9) | 1 (5.3) | |
Alive | 652 (88.7) | 638 (89.1) | 14 (73.7) | |
Lost to follow-up | 54 (7.4) | 50 (7.0) | 4 (21.1) |
*HEV, hepatitis E virus; MSM, men who have sex with men; IDU, intravenous drug use; BMI, body mass index; ALT, alanine aminotransferase; HAART, highly active antiretroviral therapy; NS, not significant.
1These authors contributed equally to this article.
2These authors contributed equally to this article.